Poly Medicure Limited has informed the Exchange about Investor Presentation
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure submitted its updated Investor Presentation for March 2026 to BSE and NSE. The company highlighted its scale: 15 manufacturing plants across 5 countries, 225+ medical devices, 390+ patents, and operations in 125+ countries. For 9M FY26, consolidated revenue grew 9.1% YoY to Rs 1,340.7 Cr, driven by 17.6% growth in domestic sales, though EBITDA margin declined 161 bps to 25.8% due to higher employee costs (+25.4%) and acquisition-related expenses. Strategic priorities include completing the Palwal plant by FY27, launching new products in cardiology, critical care and neonatology over the next 3-4 years, doubling R&D spends, and expanding the US and Europe presence through recent acquisitions (PendraCare, Citieffe, Plan-1 Health).
The presentation signals continued revenue growth momentum (especially domestic, up 17.6%) and ambitious expansion plans, but the 161 bps EBITDA margin contraction and rising employee/acquisition costs may temper near-term profitability expectations. Shareholders should watch for execution on the FY27 capacity additions and new product launches.